Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL20510487

Cc1cc(N2CC3(CNC3)C2)ccn1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 2/20 0.39
▸ TMEM97 Q5BJF2 1/20 0.38
▸ HRH4 Q9H3N8 3/20 0.38
▸ CYP2C9 P11712 4/20 0.38
▸ TSHR P16473 1/20 0.38
▸ HRH3 Q9Y5N1 2/20 0.36
▸ ELOVL1 Q9BW60 1/20 0.35
▸ ABL1 P00519 1/20 0.35
▸ CYP3A4 P08684 3/20 0.35
▸ CYP2C19 P33261 2/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ AOC3 Q16853 1/20 0.35
▸ TLR9 Q9NR96 1/20 0.35
▸ TLR8 Q9NR97 1/20 0.35
▸ TLR7 Q9NYK1 1/20 0.35
▸ HSD17B10 Q99714 2/20 0.34
▸ USP2 O75604 1/20 0.34
▸ SLC2A1 P11166 2/20 0.34
▸ CHRM4 P08173 1/20 0.34
▸ RBP4 P02753 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12758920 0.87 TMEM97 (0.42) MAPK1TMEM97HRH4CYP2C9TSHR
Trifluoroacetic Acid SCHEMBL20510933 0.85 RBP4 (0.39) MAPK1TMEM97HRH4CYP2C9TSHR
Trifluoroacetic Acid SCHEMBL20510269 0.82 CYP2C9 (0.51) MAPK1CYP2C9TSHRCYP3A4CYP2C19
Trifluoroacetic Acid SCHEMBL20510311 0.78 CHRNA7 (0.48) TLR9TLR8TLR7CHRM4
Trifluoroacetic Acid SCHEMBL21590371 0.78 RBP4 (0.35) TMEM97HRH4HRH3CYP3A4HSD17B10
Trifluoroacetic Acid SCHEMBL20510323 0.77 CYP2C19 (0.50) MAPK1CYP2C9TSHRCYP3A4CYP2C19
Trifluoroacetic Acid SCHEMBL21048277 0.75 DPP4 (0.48) CYP2C9TSHRCYP2C19
Trifluoroacetic Acid SCHEMBL30059747 0.75 DPP4 (0.48) CYP2C9TSHRCYP2C19
Trifluoroacetic Acid SCHEMBL23850306 0.75 ALDH1A1 (0.51) MAPK1CYP2C9TSHRCYP3A4CYP2C19
Trifluoroacetic Acid SCHEMBL20798079 0.75 HSD17B10 (0.50) CYP2C9TSHRCYP3A4CYP2C19SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577251-B2 Modulators of the sigma-2 receptor and their method of use Temple University—Of the Commonwealth System of Higher Education (US) 2026-03-17 — — US disclosed
EP-3600290-B1 NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE UNIV TEMPLE (US) 2025-06-04 — — EP disclosed
US-20240300954-A1 NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2024-09-12 — — US disclosed
US-11820774-B2 Modulators of the sigma-2 receptor and their method of use Temple University—Of the Commonwealth System of Higher Education (US) 2023-11-21 — — US disclosed
US-20210363145-A1 NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2021-11-25 — — US disclosed
US-10961249-B2 Modulators of the sigma-2 receptor and their method of use TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2021-03-30 — — US disclosed
US-20200039985-A1 NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2020-02-06 — — US disclosed
EP-3600290-A1 NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE Temple University - Of The Commonwealth System of Higher Education (US) 2020-02-05 — — EP disclosed
WO-2018175188-A1 NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2018-09-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10961249-B2 Modulators of the sigma-2 receptor and their method of use SIGMAR1, TMEM97, OPRM1 MAPK1 3239/4885TMEM97 2/4885HRH4 193/4885
US-20200039985-A1 NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE SIGMAR1, TMEM97, OPRL1 MAPK1 3263/4885TMEM97 2/4885HRH4 214/4885
US-20210363145-A1 NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE SIGMAR1, TMEM97, OPRL1 MAPK1 3263/4885TMEM97 2/4885HRH4 214/4885
US-11820774-B2 Modulators of the sigma-2 receptor and their method of use SIGMAR1, TMEM97, OPRM1 MAPK1 3239/4885TMEM97 2/4885HRH4 193/4885
US-20240300954-A1 NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE SIGMAR1, TMEM97, OPRL1 MAPK1 3263/4885TMEM97 2/4885HRH4 214/4885
US-12577251-B2 Modulators of the sigma-2 receptor and their method of use SIGMAR1, CHRNA6, NR3C2 MAPK1 2596/4885TMEM97 13/4885HRH4 232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback